Targovax Presented ONCOS-102 Poster at 13th International Adenovirus Meeting
OSLO, Norway, Oct. 1, 2018 /PRNewswire/ -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company presented at the following conference:
13th International Adenovirus Meeting
Date: 27 September 2018
Presenter: Lukasz Kuryk, Director Clinical Science
Poster session: 20:00 – 23:00
Venue: San José Vista Hermosa, Mexico
Abstract title: "Anti-tumor specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model"
Please see the poster below:
Contact:
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
http://mb.cision.com/Public/17093/2632463/b0f3bb45e90575ef.pdf
1809 Poster ONCOS-102
View original content:http://www.prnewswire.com/news-releases/targovax-presented-oncos-102-poster-at-13th-international-adenovirus-meeting-300721691.html
SOURCE Targovax
Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, Oslo:TRVX, RICS:TRVX.OL